Skip to content

Editas Medicine, Inc.

EDIT

CIK 0001650664 · Biological Products, (No Diagnostic Substances) · Nasdaq

← back to feed
Revenue (TTM)
$18.61M
+25.4% YoY Q1 Apr 2026
Net Income (TTM)
−$179.42M
+32.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.09
+37.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-952.5%
Q1 Apr 2026
Net Margin
-964.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$160.42M
Q1 Apr 2026
Cash
$123.65M
Q1 Apr 2026
Total Debt
$54.68M
Q1 Apr 2026
Shares Outstanding
97.91M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings